CapnoPen^® (CP–001) is CapnoPharm’s reference PIPAC nebulizer and the most widely established device for intraperitoneal aerosol chemotherapy. With extensive clinical experience and proven performance, it generates a stable aerosol with fine, narrowly distributed droplets and a uniform spray cone, supporting reliable and homogeneous drug dispersion in the peritoneal cavity.

In technical and preclinical comparisons with other PIPAC-compatible nebulizers, CapnoPen^® demonstrated consistently stable aerosolization¹ and superior oncological outcomes², including stronger tumor regression and improved histopathology results.

CE-certified under MDR Class IIb, CapnoPen^® set the benchmark as the first device approved for effective and reproducible PIPAC drug delivery and remains the only PIPAC nebulizer authorized to aerosolize not only chemotherapy but also DNA, RNA, nanomolecules, viruses and immunotherapy into body cavities.